Tradestie Institutional Equity Comparison Engine

DERM vs BOLD โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BOLD Overall Edge

BOLD Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Boundless Bio, Inc. Common Stock (BOLD) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while DERM counters with relative strength in Valuation. Fundamentally, DERM trades at 8.3x Forward P/E with -2.9% operating margin (+7.6% YoY revenue) versus BOLD at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DERM sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against BOLD sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner DERM
DERM 8.3x vs BOLD N/M Fwd P/E
Growth & Margin Winner BOLD
Op Margin -2.9% vs 0.0% ยท YoY +7.6% vs +0.0%
Momentum & Technical Winner BOLD
1Y -56.9% vs +101.7% ยท 52W Pos 1% vs 62%
Options & Structure Winner BOLD
BREAKDOWN (4th %ile IV) vs UNCLASSIFIED (N/A IV)
DERM NASDAQ
Journey Medical Corporation Common Stock
Pharmaceutical Preparations
$3.30
-7.04% 1D
Market Cap $100.2M
1M Return -35.17%
1Y Return -56.86%
Forward P/E 8.3x
Unified AI Score
40.9 / 100 SELL
Tech 25.0 Fund 47.0 Flow 72.0 Mom 59.0
BOLD NASDAQ
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
1M Return -4.92%
1Y Return +101.74%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DERM -56.86% BOLD +101.74% Spread: +158.6 pp (BOLD Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DERM TTM Op. Margin: -2.9% BOLD TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DERM vs BOLD. Trailing 12-month operating profitability (DERM -2.9% vs BOLD 0.0%) and valuation multiples (DERM 8.3x vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DERM (6) vs BOLD (4)
Institutional Metric DERM BOLD Criterion Row Winner
Market Capitalization Scale $100.2M $56.2M Larger Scale DERM
Trailing P/E Ratio Valuation 17.6x N/M Lower Multiple DERM
Forward P/E Ratio Valuation 8.3x N/M Lower Multiple DERM
Revenue Growth (YoY) Growth +7.6% +0.0% Higher Growth DERM
Operating Margin (TTM) Profitability -2.9% 0.0% Higher Margin BOLD
Net Profit Margin Profitability -7.3% 0.0% Higher Margin BOLD
Return on Equity (ROE) Capital Efficiency -17.6% -64.6% Higher ROE DERM
52-Week Range Position Momentum 1% ($3โ€“$10) 62% ($1โ€“$3) Stronger Trend BOLD
Beta / 30D Volatility Risk Regime 2.08ฮฒ ยท 77% Vol -0.08ฮฒ ยท 28% Vol Lower Realized Risk BOLD
Unified Institutional Score Composite Signal 40.9 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite DERM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DERM vs BOLD Buy Guide
DERM BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live DERM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BOLD Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DERM nor BOLD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.